

General Battery Corporation (the fourth signatory to the Decree and a major generator of waste disposed of at the Site) providing access to the Site, the Shaners' cooperation during the cleanup, permanent use restrictions on the Site and preservation of a portion of the Site as a permanent wilderness area; and (3) to waive any claims for Takings under the Fifth Amendment of the United States Constitution and claims for statutory relocation benefits. By signing the Decree, General Battery Corporation ("GBC") has agreed: (1) To reimburse the Hazardous Substances Superfund in the amount of \$3,000,000, (2) to pay \$24,000 in past natural resource costs to the federal natural resources trustees (the National Oceanographic and Atmospheric Administration ("NOAA") and the Department of Interior ("DOI")); (3) to pay certain of EPA's future response costs; (4) to pay up to \$10,000 of DOI's future costs; (5) to perform those activities required by the Record of Decision ("ROD") for Operable Unit Two of the final Site remedy (excavating lead contaminated soil above 1000 parts per million, transport of the contaminated soil to GBC's off-Site innovative thermal treatment facility, and treatment of the deep and shallow groundwater) and complete those activities required by the ROD for Operable Unit One of the final Site remedy (constructing a fence around the property); and (6) to perform extensive work to protect natural resources at the Site as required by DOI and NOAA.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed consent decree. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, Department of Justice, Washington, D.C. 20530, and should refer to *United States v. Terry Shaner, et al.*, DOJ Ref. # 90-11-3-76.

The proposed consent decree may be examined at the Office of the United States Attorney, Eastern District of Pennsylvania, 615 Chestnut Street, Suite 1250, Philadelphia, Pennsylvania, 19106-4476; the Region III Office of the Environmental Protection Agency, 841 Chestnut Building, Philadelphia, Pennsylvania, 19107; and at the Consent Decree Library, 1120 G Street NW., 4th Floor, Washington, DC 20005, (202) 624-0892. A copy of the proposed consent decree may be obtained in person or by mail from the Consent Decree Library, 1120 G Street NW., 4th Floor, Washington, DC 20005. In requesting a copy of the body of the proposed decree, please refer to the

referenced case and enclose a check in the amount of \$41.25 (25 cents per page reproduction costs), for each copy. The check should be made payable to the Consent Decree Library. If copies of the proposed consent decree attachments are requested, enclose \$167.25 (an additional \$126.00 is required for the attachments).

Bruce S. Gelber,

Acting Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 95-18429 Filed 7-26-95; 8:45 am]

BILLING CODE 4410-01-M

Drug Enforcement Administration

[DEA #134P]

Controlled Substances: Proposed Aggregate Production Quotas for 1996

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed aggregate production quotas for 1996.

SUMMARY: This notice proposes initial 1996 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act. **DATES:** Comments or objections should be received on or before August 28, 1995.

ADDRESSES: Send comments or objections to the Deputy Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn: DEA Federal Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug & Chemical Evaluation Section, Drug Enforcement Administration, Washington, D.C. 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations.

The Administrator, in turn, has redelegate this function to the Deputy Administrator pursuant to § 0.104 of Title 28 of the Code of Federal Regulations.

The quotas are to provide adequate supplies of each substance for: (1) The estimated medical, scientific, research, and industrial needs of the United States; (2) lawful export requirements; and (3) the establishment and maintenance of reserve stocks.

In determining the below listed proposed 1996 aggregate production quotas, the Deputy Administrator considered the following factors: (1) Total actual 1994 and estimated 1995 and 1996 net disposals of each substance by all manufacturers; (2) estimates of 1995 year-end inventories of each substance and of any substance manufactured from it and trends in accumulation of such inventories; and (3) projected demand as indicated by procurement quota applications filed pursuant to § 1303.12 of title 21 of the Code of Federal Regulations.

Pursuant to § 1303.23(c) of title 21 of the Code of Federal Regulations, the Deputy Administrator of the DEA will, in early 1996, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 1995 year-end inventory and actual 1995 disposition data supplied by quota recipients for each basic class of Schedule I or II controlled substance.

Therefore, under the authority vested in the Attorney General by section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by § 0.100 of title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to § 0.104 of title 28 of the Code of Federal Regulations, the Deputy Administrator hereby proposes that the aggregate production quotas for 1996 for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

Basic class	Proposed 1996 quotas
Schedule I:	
Acetylmethadol	7
Alphacetylmethadol	7
Aminorex	7
Cathinone	9
Difenoxin	14,000
Dihydromorphine	7
2,5-Dimethoxyamphetamine	10,650,000
Dimethylamphetamine	7
Ethylamine Analog of	
Phencyclidine	5
N-Ethylamphetamine	7
Lysergic acid diethylamide	58
Mescaline	7
Methaqualone	17
Methcathinone	9
4-Methoxyamphetamine	17
4-Methylaminorex	2
3,4-	
Methylenedioxyamphetami- ne	17
3,4-Methylenedioxy-N- ethylamphetamine	27
3,4-	
Methylenedioxymethamph- etamine	42
3-Methylfentanyl	14